Clinical Trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Study acronym: MountainTAP-29
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Protocol Amendment History 4 changes
notable Trial sites expanded: 311 -> 318 locations 2026-06-27
notable Trial sites expanded: 288 -> 311 locations 2026-06-06
notable Trial sites expanded: 277 -> 288 locations 2026-05-19
notable Trial sites expanded: 264 -> 277 locations 2026-05-07
Trial Details
NCT Number NCT07063745
Lead Sponsor Bristol-Myers Squibb
Conditions Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Enrollment 590 participants
Start Date 2026-01-02
Primary Completion 2031-08-12 (estimated)
Study Completion 2031-08-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-10